MEDIUM confidence: 100% data completeness, but the composite (54) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
| Metric (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $15.9B— | $19.1B+20.2% | $19.9B+4.5% | $19.9B-0.4% | $21.5B+8.3% |
| EPS (dil.) | $10.09— | $16.04+59.0% | $21.84+36.2% | $27.12+24.2% | $28.48+5.0% |
| Free Cash Flow | $2.2B— | $2.6B+17.5% | $3.0B+14.8% | $3.3B+12.0% | $3.9B+16.9% |
| Gross Margin | 27.7% | 33.9%+6.2pp | 35.9%+2.0pp | 36.9%+0.9pp | 37.7%+0.8pp |
| Operating Margin | 17.7% | 16.9%-0.9pp | 19.6%+2.7pp | 20.5%+0.9pp | 21.6%+1.1pp |
| Net Margin | 8.3% | 10.9%+2.6pp | 14.3%+3.3pp | 17.8%+3.5pp | 17.0%-0.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $1153 (last qtr, 10 analysts) → $1051 (last mo, 3) (-8.9%).
Buy-rated share 76% → 70% over ~3 months (-6pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $8.31 | $9.27 | +11.6% |
| Apr 2026 | $7.84 | $8.17 | +4.2% |
| Jan 2026 | $7.16 | $7.65 | +6.8% |
| Nov 2025 | $6.62 | $7.22 | +9.1% |
| Aug 2025 | $7.10 | $7.69 | +8.3% |
| May 2025 | $6.72 | $6.94 | +3.3% |
| Jan 2025 | $6.23 | $6.53 | +4.8% |
| Oct 2024 | $6.14 | $6.20 | +1.0% |
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 4.3%/yr (revenue basis).
Base free cash flow $3.4B (avg FY2024–FY2026; latest year $3.9B) · equity value $113.9B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$18.6M over 180 days (0 open-market buys, 17 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 54 for Parker-Hannifin Corporation suggests a neutral outlook, with the stock's strengths and weaknesses balancing out. The company scores high on profitability, with a notable ROE of 25.1%, and exhibits relatively low risk, with a beta of 1.1. However, it trades at a premium, as indicated by its P/E of 31.2 and P/B of 7.4, which drags down its value score. The long-term and short-term scores are relatively aligned, with only a 2-point difference, indicating a consistent outlook.